COVID-19 and Lung Ultrasound Utility

Covid19 Clinical Trial

Official title:

The Utility of Self-administered Lung Ultrasound in Patients With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04591158
• Other study ID #: 0001
• Status: Completed
• Phase: N/A
• Start date: September 15, 2020
• Est. completion date: June 9, 2021

Study information

• Verified date: July 2021
• Source: Bridge to Health Medical and Dental USA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ultrasounds are usually done by a specially trained health professional in the hospital or emergency department (ED) setting. Using a novel single-probe device, the ultrasound can be plugged into an iOS / Android device. The purpose of this research is to assess the usefulness of lung ultrasound imaging, performed by the patient in the home setting for the management of the COVID-19 disease using this novel highly-portable ultrasound.

Description:

This will be a prospective self-controlled design. The study subjects will receive a telehealth visit from a healthcare provider (HCP) to assess for any change in their COVID-19 symptoms. The HCP will recommend the patient remain at home, or to go to an emergency department based on standard of care and clinical decision making. Subsequently, the study subjects will receive a teleguidance session with a Radiologist who is trained in lung ultrasound (LUS) in order to obtain images of their chest. The physician performing LUS remotely will report LUS findings in a standard quality assurance (QA) document, including image quality, interpretation, and recommendations. This QA report will be study data and not shared with the patient. The two providers will be blinded, except when there is a disagreement between the Telemed LUS and clinical interview. The study staff will determine when this disagreement occurs. They will notify the study investigators and radiologist, who will then discuss and come to an agreement within 24 hours. If deemed concerning, they will then contact the HCP and unblind them as to the radiographic findings. There will be no delay in medical care advised by the subject's HCP. Specifically, the nurse will inform the HCP by a phone call that the physician performing LUS remotely found a significant change in LUS findings. The HCP will then be given access to the LUS report (as well as images if desired), and will review the decision to seek medical care with the telemed doctor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: June 9, 2021
• Est. primary completion date: June 9, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

Inclusion Criteria:

• Must be 18 years or older and able to provide a valid informed consent.
• Must have a nasal swab positive RT-PCR for COVID-19
• Must have access to Wi-Fi at home

Exclusion Criteria:

• Subjects unwilling or unable to directly provide consent.
• The following vulnerable study subject populations will not be eligible: prisoners, mentally impaired, or disadvantaged groups.
• Any condition deemed by the principal investigator, in his or her judgment, that may impact the subject's ability to meet the requirements necessary to collect the exam data required.

Related Conditions & MeSH terms

• Covid19
• Lung Infection

Intervention

Device:
• Butterfly iQ
The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.

Locations

Country	Name	City	State
Canada	Markham Stouffville Hospital	Markham	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Bridge to Health Medical and Dental USA

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	If patients can perform lung ultrasound.	Patients will perform a lung ultrasound with teleguidance from a medical professional. This will be taken daily and monitored by an expert clinician who can guide based on the remote live transmission and probe position.	This will take place over a 14 day period of time.
Secondary	Correlate LUS radiographic findings with patient outcomes	The LUS radiographic findings will be assessed to determine a possible correlation between the radiographic findings and disease timeline, clinical symptoms, ER visits, and hospital admissions. The score from radiographic assessment will be compared to the course of a subject's illness.	These correlations will be assessed over a 14-day period of time while the patient is enrolled in the study.